Vimentin Antibody (LN-6) - Azide and BSA Free

Immunohistochemistry-Paraffin: Vimentin Antibody (LN-6) - Azide and BSA Free [NBP2-47949] - Human Melanoma stained with Vimentin Monoclonal Antibody (LN-6).

• Reactivity: Hu, Mu, Rt, Po, Bv, Fe, Rb, Sh
• Applications: Flow, IHC, CyTOF-ready
• Clone: LN-6
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: Azide and BSA Free
• Concentration: 1.0 mg/ml

Vimentin Antibody (LN-6) - Azide and BSA Free Summary

• Description: 1.0 mg/ml of antibody purified from Bioreactor Concentrate. Prepared in 10mM PBS WITHOUT BSA & azide. Also available at 200 ug/ml WITH BSA & azide (NBP2-44832).
  
  Antibody with azide - store at 2 to 8C. Antibody without azide - store at -20 to -80C.
• Immunogen: Human thymic nuclear extract (Uniprot: P08670)
• Localization: Cytoplasmic
• Marker: Mesenchymal Cell Marker
• Specificity: This monoclonal antibody reacts with a 58kDa protein identified as vimentin. It reacts with a non-hematopoietic epitope of vimentin and shows no cross-reaction with other closely related intermediate filament proteins (IFPs) such as desmin, keratin, neurofilament, and glial fibrillary acid protein. Vimentin is ubiquitously expressed in mesenchymal cells such as fibroblasts, smooth muscle cells, and endothelium. Antibody against vimentin is useful as part of an antibody panel for differential diagnosis of tumors of unknown origin.Ab-2 does not react with leukocyte common antigen-positive tissues such as lymphomas and leukemias.
• Isotype: IgM Kappa
• Clonality: Monoclonal
• Host: Mouse
• Gene: VIM
• Purity: Protein L or PEG purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 0.5 - 1.0 ug/million cells in 0.1 ml
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin 1 - 2 ug/ml
• Application Notes: Use in Flow Cytometry reported in scientific literature (PMID:34276989).
• Theoretical MW: 53.6 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Reactivity Notes

Use in Rat reported in scientific literature (PMID:34276989)

Packaging, Storage & Formulations

• Storage: Store at -20 to -80C. Avoid freeze-thaw cycles.
• Buffer: 10 mM PBS
• Preservative: No Preservative
• Concentration: 1.0 mg/ml
• Purity: Protein L or PEG purified

Alternate Names for Vimentin Antibody (LN-6) - Azide and BSA Free

• epididymis secretory sperm binding protein
• FLJ36605
• VIM
• Vimentin

Background

Vimentin is a type III intermediate filament (IF) protein, encoded by the VIM gene, that plays an essential role in cytoskeletal function and is largely expressed by mesenchymal cell such as endothelial cells, fibroblasts, and immune cells (1). Human vimentin monomer protein is 466 amino acids (aa) in length with a theoretical molecular weight of ~54 kDa (2). Vimentin protein contains a central rod domain composed of four alpha-helices which is flanked by an N-terminal head domain and C-terminal tail domain (1,3). Vimentin monomers dimerize to form more complex structures resulting in the assembly of eight tetramers, referred to as unit-length filaments, which then assemble into full-length intermediate filaments that are 10-12 nm wide (1,3,4).

Activated macrophages have been shown to secrete phosphorylated vimentin which can be stimulated by a variety of pathophysiological factors including oxidized low-density lipoproteins and TNF-alpha or inhibited by IL-10 (1). The vimentin protein is often expressed at the cell surface playing a role in cell-cell interactions, tissue damage and repair, immune response, and pathogen recognition (1). Vimentin functions in many cytoskeletal processes including cell migration, which is highlighted by its upregulation during epithelial-to-mesenchymal transition (EMT) (4,5). Vimentin is a commonly used marker for EMT and is expressed by many tumor types (5). For example, high metastasis of oral squamous cell carcinomas also showed high vimentin positive expression in immunohistochemical staining analysis (5). A number of vimentin targeting compounds are in cancer-related clinical trials, however, given the multifunctional role of vimentin, the effect of inhibition on non-malignant cells needs to be thoroughly examined (5).

References

1. Ramos, I., Stamatakis, K., Oeste, C. L., & Perez-Sala, D. (2020). Vimentin as a Multifaceted Player and Potential Therapeutic Target in Viral Infections. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21134675

2. Uniprot (P08670)

3. Morrow, C. S., & Moore, D. L. (2020). Vimentin's side gig: Regulating cellular proteostasis in mammalian systems. Cytoskeleton (Hoboken, N.J.). https://doi.org/10.1002/cm.21645

4. van Bodegraven, E. J., & Etienne-Manneville, S. (2020). Intermediate filaments against actomyosin: the david and goliath of cell migration. Current Opinion in Cell Biology. https://doi.org/10.1016/j.ceb.2020.05.006

5. Strouhalova, K., Prechova, M., Gandalovicova, A., Brabek, J., Gregor, M., & Rosel, D. (2020). Vimentin Intermediate Filaments as Potential Target for Cancer Treatment. Cancers. https://doi.org/10.3390/cancers12010184

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Vimentin Antibody (NBP2-47949)(1)

Publication using NBP2-47949

• Piera L, Szymanski J, Juszczak M et al. Histamine is involved in the regulation of collagen content in cultured heart myofibroblasts via H(2), H(3) and H(4) histamine receptors Biomed Rep 2021-08-01 [PMID: 34276989] (FLOW)
  
  Details:
  Citation using the Azide and BSA Free format of this antibody.

Bioinformatics

• Gene Symbol: VIM